Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Cutting Two Amino Acids Slowed Prostate Cancer in Mice (opens in a new tab)

scitechdaily.com · 2026-09-10

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. 2 other points were not covered by the paper.

  • 2 supported
  • 1 overstated
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Two of five check out. Two claims the study doesn't address.

  • 2 supported
  • 1 overstated
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedResearchers found that propionyl-CoA can act as a signal that turns on cholesterol production, helping prostate cancer cells adjust to hormone-deprived conditions and develop more aggressive characteristics.View evidenceHide evidence

Why this verdict

The profile supports that propionyl-CoA functions as a signalling molecule that stabilizes SREBP2 and enhances cholesterol biosynthesis, and that the pathway sustains AR signalling under androgen deprivation. However, the story’s unhedged phrasing that this helps cells “develop more aggressive characteristics” goes beyond the abstract-level evidence, which does not provide concrete aggression/progression phenotypes for that part of the claim.

1

Study evidence

Propionyl-CoA stabilizes nuclear SREBP2 via site-specific lysine propionylation, enhancing SREBP2 transcriptional activity; this effect is linked to propionyl-CoA availability in prostate cancer cells.

“propionyl-CoA functions as a signalling molecule that stabilizes nuclear sterol regulatory element-binding protein 2 (SREBP2) through site-specific lysine propionylation, thereby enhancing its transcriptional activity.”
2

Study evidence

Isoleucine and valine catabolism is the primary source of intracellular propionyl-CoA in prostate cancer cells.

“This activation promotes cholesterol biosynthesis, fuels de novo androgen production, and sustains androgen receptor signalling under metabolic and therapeutic stress, including androgen deprivation.”
Claim 2 of 5Not coveredIn mouse models, restricting isoleucine and valine slowed prostate tumor growth and reduced spread of cancer cells to the lungs, while increasing propionyl-CoA promoted tumor growth and greater lung colonization.View evidenceHide evidence

As statedslowed tumor growth; reduced spread to the lungs

Why this verdict

The abstract-level profile does not report mouse-model outcomes, tumor-growth slowing, lung colonization/spread, or propionyl-CoA-increase experiments producing greater lung colonization. Unit 0004 notes only a potential targeting strategy and possible intervention studies, without abstract-level details. This claim may depend on full-paper evidence, but it is not verifiable from the supplied abstract-depth profile.

1

Study evidence

Isoleucine and valine catabolism is reported as the primary source of intracellular propionyl-CoA in prostate cancer cells.

“highlight targeting isoleucine and valine metabolism as a potential strategy to disrupt lipid reprogramming in prostate cancer.”
Claim 3 of 5Not coveredThe story says the pathway may eventually be targeted with drugs or, if clinical studies support it, dietary strategies that lower isoleucine and valine, possibly alongside enzalutamide.View evidenceHide evidence

Why this verdict

The abstract supports only the general therapeutic implication that targeting isoleucine/valine metabolism could be a potential strategy to disrupt lipid reprogramming in prostate cancer. The story’s specific speculation about drugs, dietary lowering of isoleucine/valine, clinical-study prerequisites, and possible use alongside enzalutamide is more detailed than the abstract-depth profile can verify, even though it is hedged.

1

Study evidence

Isoleucine and valine catabolism is reported as the primary source of intracellular propionyl-CoA in prostate cancer cells.

“highlight targeting isoleucine and valine metabolism as a potential strategy to disrupt lipid reprogramming in prostate cancer.”
Claim 4 of 5SupportedWeill Cornell Medicine investigators traced a possible route of prostate-cancer resistance to amino acid metabolism, where a metabolic byproduct can keep cholesterol production active even when the cell would normally shut it down.View evidenceHide evidence

Why this verdict

The abstract-level profile supports a hedged mechanistic claim that isoleucine/valine catabolism supplies propionyl-CoA, that propionyl-CoA acts as a signalling molecule, and that this pathway promotes cholesterol biosynthesis and sustains androgen-receptor signalling under androgen deprivation/therapeutic stress. The story’s wording is appropriately tentative about a possible route of hormone-therapy adaptation/resistance.

1

Study evidence

Catabolism of isoleucine and valine is identified as the primary source of intracellular propionyl‑CoA in prostate cancer cells.

“We show that the catabolism of branched-chain amino acid, specifically isoleucine and valine, is the primary source of intracellular propionyl-CoA in prostate cancer cells.”
2

Study evidence

Propionyl-CoA stabilizes nuclear SREBP2 via site-specific lysine propionylation, enhancing SREBP2 transcriptional activity; this effect is linked to propionyl-CoA availability in prostate cancer cells.

“propionyl-CoA functions as a signalling molecule that stabilizes nuclear sterol regulatory element-binding protein 2 (SREBP2) through site-specific lysine propionylation, thereby enhancing its transcriptional activity.”
Claim 5 of 5SupportedThe preclinical study, published in Nature Metabolism, focused on propionyl-CoA, a compound generated when the essential amino acids isoleucine and valine are broken down during normal energy metabolism.View evidenceHide evidence

Why this verdict

The scientific substance is supported: the profile says isoleucine and valine catabolism is the primary source of intracellular propionyl-CoA in prostate cancer cells. The profile also supports that the work is preclinical/basic research. The supplied profile does not independently verify the journal venue, but the metabolic-focus claim is supported by the abstract evidence.

1

Study evidence

Catabolism of isoleucine and valine is identified as the primary source of intracellular propionyl‑CoA in prostate cancer cells.

“We show that the catabolism of branched-chain amino acid, specifically isoleucine and valine, is the primary source of intracellular propionyl-CoA in prostate cancer cells.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Propionyl-CoA acts as a signalling molecule that stabilizes nuclear SREBP2 through site-specific lysine propionylation and increases SREBP2 transcriptional activity.

    The story reflects the broad idea that propionyl-CoA is a signal that activates cholesterol production, but it does not include the paper’s central mechanistic detail: SREBP2 stabilization via site-specific lysine propionylation.

    From in_vitro

  • The supplied abstract-depth profile does not provide quantitative effect sizes, detailed methods, specific models, sample sizes, or statistical robustness for the mechanistic findings.

    The story mentions that the work is preclinical and that clinical studies would be needed, but it does not convey the abstract-level limitation that quantitative and methodological details are unavailable in the supplied evidence.

    From In vitro stable-isotope tracing and targeted acyl‑CoA metabolomics; in_vitro; in_vitro; other

  • From the supplied abstract-depth profile, in vivo mouse tumor-growth and lung-spread outcomes are not available.

    The story presents specific mouse-model tumor-growth and lung-colonization results, but the supplied abstract-level profile does not contain those outcomes or enough intervention detail to verify them.

    From other

4 things the story did carry across
  • Isoleucine and valine catabolism is identified as the primary source of intracellular propionyl-CoA in prostate cancer cells.
  • The propionyl-CoA/SREBP2 axis promotes cholesterol biosynthesis, de novo androgen production, and sustained androgen-receptor signalling under metabolic and therapeutic stress, including androgen deprivation.
  • Targeting isoleucine and valine metabolism is proposed as a potential strategy to disrupt lipid reprogramming in prostate cancer.
  • The abstract-depth profile does not establish clinical efficacy or human validation of dietary or drug targeting of this pathway.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroPropionyl-CoA acts as a signalling molecule that stabilizes SREBP2 via site-specific lysine propionylation, increasing SREBP2 transcriptional activity.in vitroExpand

In plain English

The paper reports that intracellular propionyl-CoA functions as a signalling metabolite in prostate cancer cells that stabilizes nuclear SREBP2 via site-specific lysine propionylation, which in turn enhances SREBP2 transcriptional activity; this stabilizing effect is presented as causally linked to propionyl-CoA availability.

Key findings

  • Propionyl-CoA stabilizes nuclear SREBP2 via site-specific lysine propionylation, enhancing SREBP2 transcriptional activity; this effect is linked to propionyl-CoA availability in prostate cancer cells.
“propionyl-CoA functions as a signalling molecule that stabilizes nuclear sterol regulatory element-binding protein 2 (SREBP2) through site-specific lysine propionylation, thereby enhancing its transcriptional activity.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2in vitroBranched-chain amino acid (BCAA) catabolism—specifically isoleucine and valine—is the primary source of intracellular propionyl-CoA in prostate cancer cells.In vitro stable-isotope tracing and targeted acyl‑CoA metabolomicsExpand

In plain English

In prostate cancer cell models, catabolism of the branched-chain amino acids isoleucine and valine supplies the intracellular propionyl-CoA pool, with these two BCAAs identified as the primary source of propionyl-CoA.

Key findings

  • Catabolism of isoleucine and valine is identified as the primary source of intracellular propionyl‑CoA in prostate cancer cells.
“We show that the catabolism of branched-chain amino acid, specifically isoleucine and valine, is the primary source of intracellular propionyl-CoA in prostate cancer cells.”
What this piece can’t prove

2 further details could not be confirmed from the summary.

3in vitroSREBP2 activation driven by propionyl-CoA enhances cholesterol biosynthesis, promotes de novo androgen production, and sustains androgen receptor signalling under metabolic and therapeutic stress (including androgen deprivation).in vitroExpand

In plain English

The paper reports that intracellular propionyl-CoA, produced primarily from isoleucine and valine catabolism in prostate cancer cells, acts as a signalling metabolite that stabilizes nuclear SREBP2 via site-specific lysine propionylation to enhance its transcriptional activity. SREBP2 activation is described to increase cholesterol biosynthesis and lipid accumulation, which in turn fuels de novo androgen synthesis and helps sustain androgen receptor (AR) signalling under metabolic and therapeutic stress, including androgen deprivation.

Key findings

  • Isoleucine and valine catabolism is the primary source of intracellular propionyl-CoA in prostate cancer cells.
  • Propionyl-CoA stabilizes nuclear SREBP2 via site-specific lysine propionylation and enhances SREBP2 transcriptional activity.
“This activation promotes cholesterol biosynthesis, fuels de novo androgen production, and sustains androgen receptor signalling under metabolic and therapeutic stress, including androgen deprivation.”
What this piece can’t prove
  • Summary is based on the abstract; methodological detail, quantitative results, and specific models are not provided here.
  • The abstract does not specify which cell lines or whether in vivo/clinical validation was performed for the stress-adaptation and AR signalling findings.

1 further detail could not be confirmed from the summary.

4otherTargeting isoleucine/valine metabolism is a plausible strategy to disrupt lipid reprogramming and prostate cancer progression (therapeutic implication).Expand

In plain English

In prostate cancer cells, catabolism of the branched-chain amino acids isoleucine and valine is reported as the primary source of intracellular propionyl-CoA. Propionyl-CoA acts as a signalling metabolite that stabilizes nuclear SREBP2 via site-specific lysine propionylation, increasing SREBP2 transcriptional activity. This drives cholesterol biosynthesis, lipid droplet accumulation, and de novo androgen production, thereby sustaining androgen receptor signalling under metabolic and therapeutic stress (including androgen deprivation). The authors state that targeting isoleucine and valine metabolism is a potential strategy to disrupt lipid reprogramming in prostate cancer.

Key findings

  • Isoleucine and valine catabolism is reported as the primary source of intracellular propionyl-CoA in prostate cancer cells.
  • Propionyl-CoA stabilizes nuclear SREBP2 via site-specific lysine propionylation, increasing SREBP2 transcriptional activity.
“highlight targeting isoleucine and valine metabolism as a potential strategy to disrupt lipid reprogramming in prostate cancer.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 37 candidate papers

And 31 more candidates considered.